mk-5684
Small moleculeexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 14, 2023 (NCT06104449)
Timeline
Indications
Mechanism of action
- Cytochrome P450 11A1INHIBITOR
CYP11A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)N1CCC(COc2coc(CN3Cc4ccccc4C3)cc2=O)CC1- Mol. weight
- 418.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314533 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06863272 | Phase 1/Phase 2 (Phase 2) | Jun 17, 2025 | Daiichi Sankyo, Merck |
| NCT06860243 | Phase 1 | Apr 11, 2025 | Merck |
| NCT06814132 | Phase 1 | Mar 14, 2025 | Merck |
| NCT06633419 | Phase 1 | Jan 2, 2025 | Merck |
| NCT06566989 | Phase 1 | Sep 19, 2024 | Merck, Orion Corporation |
| NCT06554639 | Phase 1 | Jul 11, 2024 | Merck |
| NCT06353386 | Phase 1/Phase 2 (Phase 2) | May 20, 2024 | Merck, Orion Corporation |
| NCT06136598 | Phase 1 | Dec 25, 2023 | Merck |
| NCT06136624 | Phase 3 | Dec 22, 2023 | Merck, Orion Corporation |
| NCT06136650 | Phase 3 | Dec 18, 2023 | Merck, Orion Corporation |
| NCT06104449 | Phase 1 | Nov 14, 2023 | Merck |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 11 | 11 | 3 | 2023 |
| Orion Corporation | For profit | 4 | 0 | 3 | 2023 |
| Daiichi Sankyo | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1